Australian biotechnology company Anteris Technologies announced that the US Patent and Trademark Office has issued another utility patent for its novel DurAVR transcatheter heart valve (THV).
The ASX-listed company said DurAVR THV is the first biomimetic valve of its kind, designed to mimic the performance of a healthy human heart valve.
The patent number, 11,648,107, which expires 12 September 2038, provides additional Intellectual Property (IP) protection for the differentiated heart valve technology.
This patent protects the novel single-piece tissue design with moulded leaflets and commissures attached to a frame and adds new claims to the already existing IP protection for DurAVR THV.
The company believes the exceptional clinical outcomes so far are due to the distinctive features of the DurAVR design, such as the single-piece valve construction and leaflet shape.
Anteris’ capacity to develop a substantial IP portfolio around DurAVR THV is also confirmed by this latest patent.
Commenting on the announcement, Anteris CEO Wayne Paterson said the awarding of the patent continues to underscore the company’s culture of innovation and the work done by its team of engineers.
“This new patent further enhances our broad IP protection for DurAVR THV and strengthens our competitive position in the TAVR field,” noted Paterson.
The company stated that the DurAVR 3D single-piece aortic heart valve’s distinctive design and the well-established advantages of its patented ADAPT tissue technology could offer aortic stenosis patients all over the world a treatment that could change their lives.
